Yak Antibodies Could Unlock New Treatments for Multiple Sclerosis
A gene that helps animals like yaks cope with high altitudes without any damage to their myelin sheaths, the fatty covering that protects nerves, may help treat neurological diseases like MS.
Yaks may hold the key to treating MS patients: study
Scientists have discovered that a gene found in yaks and other high-altitude animals could open the door to new treatments for multiple sclerosis and other neurological diseases. The research, which examined how these animals thrive in low-oxygen environments without suffering nerve damage, identified a genetic mechanism that protects the myelin sheath, the fatty insulating layer that surrounds nerve fibers. In MS patients, this protective covering breaks down, leading to debilitating symptoms including muscle weakness, vision problems, and difficulty with coordination and balance.
The study found that yaks, which live at elevations exceeding 14,000 feet where oxygen levels are significantly lower than at sea level, have evolved a specific gene variant that shields their myelin sheaths from damage caused by hypoxic conditions. At such extreme altitudes, the reduced oxygen supply would normally pose a serious threat to the nervous system, yet yaks and similar animals show no signs of the neurological deterioration that would be expected. Researchers believe this evolutionary adaptation could be harnessed to develop therapies that offer similar protection to human nerve cells.
Multiple sclerosis affects nearly 3 million people worldwide and currently has no cure. Existing treatments focus primarily on managing symptoms and slowing the progression of the disease rather than repairing the damaged myelin. The discovery of this protective gene in yaks has excited researchers who say it could lead to entirely new approaches that focus on preserving and restoring the myelin sheath, potentially halting or even reversing the course of the disease.
While the findings are still in the early stages, the research team expressed optimism about the potential clinical applications. Scientists plan to conduct further studies to determine how the gene's protective mechanism can be replicated in human cells and eventually translated into viable treatments. If successful, this line of research could represent a major breakthrough not only for MS patients but also for those suffering from other demyelinating conditions that affect the nervous system.